Incidence and Risk of Treatment-Related Mortality with Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Cancer Patients: A Meta-Analysis of 21 Randomized Controlled Trials

• Xing Li,

  Affiliation Department of Biotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China

  ⨯
• Bao-En Shan,

  Affiliation Centre of Scientific Research, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China

  ⨯
• Juan Wang,

  Affiliation Department of Biotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China

  ⨯
• Lian-Ping Xing,

  Affiliation Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, United States of America

  ⨯
• Xiao-Jin Guo,

  Affiliation Department of Biotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China

  ⨯
• Yue-Hua Zhang,

  Affiliation Department of Biotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China

  ⨯
• Peng-Hui Shi,

  Affiliation Department of Biotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China

  ⨯
• Zhi-Yu Wang

  * E-mail: Wangzhiyu201307@163.com

  Affiliation Department of Biotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China

  ⨯